Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of aliskiren + amlodipine + hydrochlorothiazide in essential hypertension
2008-001242-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aliskiren, amlodipine and hydrochlorothiazide in essential hypertension, sponsored by Novartis. Primary endpoint: Safety and tolerability (adverse events and laboratory abnormalities). Started Apr 2008; status: completed.
02
Drugs
aliskirenamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-001242-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001242-10.